Dario R. Tavolini

Rosario, S, Argentina

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 40 publications

Efficacy and safety of Cladribine as a therapeutic option in multiple sclerosis patients over 50 years of age: A real-world study.

Efficacy and safety of Cladribine as a therapeutic option in multiple sclerosis patients over 50 years of age: A real-world study.

Journal: Journal of the neurological sciences

Published: August 11, 2025

Real-world cost of disease-modifying treatments administered by intravenous infusion in relapsing-remitting multiple sclerosis patients from Argentina.

Real-world cost of disease-modifying treatments administered by intravenous infusion in relapsing-remitting multiple sclerosis patients from Argentina.

Journal: Multiple sclerosis and related disorders

Published: June 22, 2025

Knowledge, concerns and experiences regarding family planning and pregnancy in NMOSD: A cross-sectional study from Argentina.

Knowledge, concerns and experiences regarding family planning and pregnancy in NMOSD: A cross-sectional study from Argentina.

Journal: Multiple sclerosis and related disorders

Published: March 14, 2025

Determination of disability progression in moderately and highly disabled ambulatory patients with relapsing-remitting multiple sclerosis using the EDSS-Plus: A prospective study in Argentina.

Determination of disability progression in moderately and highly disabled ambulatory patients with relapsing-remitting multiple sclerosis using the EDSS-Plus: A prospective study in Argentina.

Journal: Multiple sclerosis and related disorders

Published: December 19, 2024

Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.

Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.

Journal: The Lancet. Neurology

Published: September 06, 2024

Real-World Effectiveness and Safety of Cladribine in Multiple Sclerosis: Longitudinal Data From the Nationwide Registry in Argentina.

Real-World Effectiveness and Safety of Cladribine in Multiple Sclerosis: Longitudinal Data From the Nationwide Registry in Argentina.

Journal: Clinical neuropharmacology

Published: July 15, 2024

Treatment strategies and responses for attacks of neuromyelitis optica spectrum disorder: A real-world retrospective cohort study.

Treatment strategies and responses for attacks of neuromyelitis optica spectrum disorder: A real-world retrospective cohort study.

Journal: Journal of the neurological sciences

Published: May 04, 2024

Comorbidities in multiple sclerosis and their influence on the choice of treatment

Comorbidities in multiple sclerosis and their influence on the choice of treatment

Journal: Revista de neurologia

Published: March 14, 2024

Traditional first-line treatment failure rates in neuromyelitis optica spectrum disorder patients included in the Argentinean registry (RelevarEM).

Traditional first-line treatment failure rates in neuromyelitis optica spectrum disorder patients included in the Argentinean registry (RelevarEM).

Journal: Multiple sclerosis and related disorders

Published: February 26, 2024

Clinical effectiveness of dimethyl fumarate in multiple sclerosis patients from Argentina.

Clinical effectiveness of dimethyl fumarate in multiple sclerosis patients from Argentina.

Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Published: February 17, 2024

Cladribine use trend in Latin America: the changes in patient profile impact in the drug effectiveness.

Cladribine use trend in Latin America: the changes in patient profile impact in the drug effectiveness.

Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Published: January 29, 2024

Occurrence of area postrema syndrome during follow-up: phenotype and influence over NMOSD activity in LATAM in real-world settings.

Occurrence of area postrema syndrome during follow-up: phenotype and influence over NMOSD activity in LATAM in real-world settings.

Journal: Journal of neurology

Published: January 20, 2024

Showing 1-12 of 40

Last Updated: 09/26/2026